Neurocrine Biosciences NBIX
NASDAQ NBIX
$152.93 -2.61 (-1.68%)
At close: Aug 20, 2026 · 4:00 PM EDT

Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022)

Neurocrine Biosciences (NBIX) posted quarterly Long-Term Debt Repayments of $279.0 million for Q2 2022, up 278900.0% on a QoQ basis from $100000.0 in Q1 2021.

Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022) Analysis & Trends

Neurocrine Biosciences has reported Long-Term Debt Repayments for 3 years, with the latest figure at $279.0 million in Q2 2022.

  • Long-Term Debt Repayments for Q2 2022 came in at $279.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $279.0 million (changed 0.0% YoY), and the FY2024 annual result was $308.8 million, changed N/A from the prior year.
  • Long-Term Debt Repayments advanced to $279.0 million in Q2 2022, from $100000.0 in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $279.0 million in Q2 2022 and troughed at $100000.0 in Q1 2021.
  • A 3-year average of $155.3 million and a median of $186.9 million in 2020 frame the typical range for Long-Term Debt Repayments.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -156,847.56
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn -
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn -
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Alkermes 8.02 Bn 7.37 Bn 397.90 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2022 279.00 Mn
Jun 30, 2022 279.00 Mn
Mar 31, 2021 100,000.00
Mar 31, 2021 100,000.00
Dec 31, 2020 186.90 Mn
Dec 31, 2020 186.90 Mn